Approved Study Database
Ref. No. | Scientific Title | Principal investigator |
---|---|---|
2023.401 | RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial | Prof. WONG Ronald Man Yeung |
2023.392 | Association between boarding time in emergency department and 30-day mortality: A single centre study in Hong Kong | Ms Poon Wing San |
2023.390 | Randomized Controlled Trial on Precision Mental Health | Prof. MAK Winnie Wing Sze |
2023.400 | Neural representations underlying successful generalization in auditory category learning | Prof. FENG Gangyi |
2023.387 | One-year course and predictors of personality change after stroke. |
Prof. TANG Wai Kwong Wai Kwong Tang |
2023.383 | Irritability in Stroke | Prof. TANG Wai Kwong |
2023.386 | Diagnosis and behaviour of papillary, in-situ and low-grade breast lesions |
Dr. LI Joshua Jing Joshua Jing Xi Li |
2023.384 | Exfoliation and aspiration cytology in tumors including low-grade neoplasms | Dr. LI Joshua |
2023.407 | 3D histologic and immunohistochemical staining for tissue reconstruction and pathological diagnosis |
Dr. LI Joshua Joshua Li |
2023.425 | Retention of first aid knowledge among holders of valid first aid certificate | Ms. Kwong Freda |
2023.379 | Boiled tree nut for oral immunotherapy in food-allergic children: a double-blind, randomized, placebo-controlled trial |
Dr. LEUNG Agnes Sze Yin 梁詩彥 |
2023.382 | Profiling age-related motoneuron loss and neuromuscular degeneration among osteosarcopenic patients in Hong Kong: a case-control study |
Dr. CUI Can 崔燦 |
2023.373 | A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma | Prof. MA Brigette Buig Yue |
2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephan Lam |
2023.374 | Hypercholesterolemia and its effect on infectious diseases | Dr. LING Lowell Lo Well |
2023.393 | Prevalence, risk factors, and outcomes of systemic sclerosis-associated interstitial lung disease in Chinese | Dr. CHAN Dennis Tin Ho |
2023.372 | Maintenance strategies in patients with metastatic colorectal cancer following first line induction palliative systemic treatment | Dr. LAI Winky Wing Ki |
2023.381 | Consultancy Study on Review of Comprehensive Child Development Service |
Ms. LUI Man Yi 雷敏儀 |
2023.370 | A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack |
Dr. LI Siu Hung SIU HUNG LI |
2023.364 | Perihilar nerve block for liver tumor ablation: A retrospective study | Dr. LAW Wing Chung |
2023.359 | A multimedia method for pre-test genetic counseling in breast cancer patients – A pilot feasibility study | Prof. CHAN Carmen |
2023.358 | The construction of lung cancer organoid using fine needle aspirate or trucut biopsy |
Prof. NG Calvin Sze Hang 吳士衡 |
2023.402 | Prospective validation of a novel machine learning derived risk score for predicting infective endocarditis among patients with Staphylococcus aureus bacteremia | Dr. LAI Christopher Koon Chi |
2023.357 | An Empirical Research of a Multimodal Decision Aid to Support Shared Decision-Making among Women Newly Diagnosed with Breast Cancer | Dr. CHOW Ka Ming |
2023.388 | Placental growth factor point-of-care testing to assess East Asian women with suspected preeclampsia: a randomized controlled trial | Prof. POON Liona Chiu Yee |
2023.375 | Systematic characterization of microbiology and inflammatory response in preterm labor syndrome and other associated obstetrics condition | Prof. POON Liona Chiu Yee |
2023.356 | Towards a stepped-care psychological intervention for delusions – a randomised controlled trial | Dr. SO Suzanne Ho Wai |
2023.360 | A retrospective study to evaluate the diagnostic accuracy of computer-aided (CADx) system in real-time characterization of colorectal ulcerative diseases |
Dr. YIP Hon Chi 葉瀚智 |
2023.362 | A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk |
Prof. YAN Bryan Ping Yen 甄秉言 |
2023.371 | Exploring Facilitators and Barriers to Exercise Prescription for Knee Osteoarthritis among Hong Kong Primary Care Physicians: A Qualitative Study |
Dr. FONG Pak Yiu Pak Yiu Fong |
2023.361 | Correlation between pleural biopsy and risk of pleural bleeding in aspirin users: a 10-year retrospective review |
Dr. YIP Wing Ho 葉永豪 |
2023.353 | Retinal displacement and functional outcome after pars plana vitrectomy for primary rheumatogenous retinal detachment |
Dr. YIU Mei Kwan N/A |
2023.389 | Global Evaluation of Cholecystectomy Knowledge and Outcomes | Prof. FUTABA Kaori |
2023.394 | A Prospective, Interventional Study on the Impact of Pharmacist Education for Thyroidectomy Patients: Experience of a Local Hospital in Hong Kong |
Ms. LI Wai Yin 李惠妍 |
2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Ms. LUK Andrea On Yan |
2023.349 | A practical clinical randomized controlled trial of traditional Chinese medicine in the treatment of Long COVID and an analysis of syndrome types and medication characteristics of traditional Chinese medicine | Dr. ZHANG Hongwei |
2023.355 | Sex- And Gender-based analysis of the Effectiveness of advanced therapies in Psoriatic Arthritis | Prof. TAM Lai Shan |
2023.347 | New Managed Care Approach for Diabetic and Hypertensive Primary Care Patients in Haizhu: a quasi-randomized study | Dr. WONG Carmen |
2023.352 | Ocular surface damage and alteration in microbiome among cocaine and ice users - a prospective observational study for their health enhancement | Dr. CHONG Kelvin Kam Lung |
2023.345 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Prof. CHAN Stephen Lam 陳林 |
2023.350 | Prediction of pediatric obstructive sleep apnea based on visual photographic analysis. |
Mr. HUANG Minhao 黄旻浩 |
2023.346 | Outcome Evaluation after Fertility Preservation |
Dr. CHUNG Jacqueline Pui Wah 鍾佩樺 |
2023.351 | Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells as a neo-adjuvant treatment in patients with resectable pancreatic cancers: a feasibility study | Prof. LAU James |
2023.348 | Brain Heath Service for Prevention of AD |
Prof. MOK Vincent 莫仲棠 |
2023.341 | The role and underlying mechanism of mitochondrial dysfunction in paraspinal muscle on the curve progression of Adolescent Idiopathic Scoliosis | Prof. LEE Wayne Yuk Wai |
2023.366 | A Retrospective Study of Comparison Between the Hong Kong Version of the Montreal Cognitive Assessment (HK-MoCA) and the Hong Kong Brief Cognitive Test (HKBC) in Detecting Post-stroke Cognitive Impairment in Stroke Patients | Mr. KWONG Ming Kin |
2023.365 | Prediction of functional recovery and length of stay of stroke in-patient rehabilitation: A data mining study | Ms. SIT Kitty Lok Mun |
2023.340 | Prognostication of Intracerebral hemorrhage – a population-based study | Dr. IP Bonaventure Yiu Ming |
2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
2023.367 | A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Dr. IP Bonaventure Yiu Ming |
Page 14 of 253.